Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innate Pharma SA ( (FR:IPH) ) has provided an update.
On August 4, 2025, Innate Pharma S.A. released its total number of shares and voting rights as of August 1, 2025, as part of its regulatory obligations under French and AMF regulations. The company reported 92,184,823 ordinary shares, 6,424 Preferred Shares 2016, and 7,581 Preferred Shares 2017, with a total of 93,962,943 theoretical voting rights and 93,944,368 exercisable voting rights. This disclosure ensures transparency and informs the market about the company’s shareholding structure, which is crucial for stakeholders and potential investors.
The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system through three therapeutic strategies: multi-specific NK Cell Engagers via its ANKET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical companies such as Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD. It is publicly listed on Euronext Paris and Nasdaq.
YTD Price Performance: -3.88%
Average Trading Volume: 151,880
Technical Sentiment Signal: Sell
Current Market Cap: €171.1M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.